Prevalence of the Diabetes, Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia over the Course of the Illness: a Cross-Sectional Study

Hert, Marc De; Winkel, Ruud van; Eyck, Dominique Van; Hanssens, Linda; Wampers, Martien; Scheen, André

doi:10.2165/00002018-200629100-00139

Cited by 68 publications

(93 citation statements)

References 35 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recent literature is relatively consistent in showing a prevalence rate of diabetes of about 15% in patients with schizophrenia or an increased risk of two to threefold as compared to the general population [17]. Such a high prevalence of diabetes and metabolic syndrome in schizophrenia over the course of the illness has been confirmed in a cross-sectional study performed by our group [25]. It is noteworthy that this higher prevalence of diabetes or abnormal glucose metabolism is also found in drug-naïve patients.…”

Section: Psychiatric Disorders and Diabetessupporting

confidence: 67%

“…Nevertheless, the lack of a significant increase in mean blood glucose in comparator groups would suggest a causal relationship between atypical antipsychotics and diabetes. [10,11,25] Several pharmacoepidemiological studies examining the association between antipsychotic drugs and diabetes have produced confusing results [38][39][40][41]. The studies rely on the analysis of computerized databases of patients treated in various organizations and are limited by the quality of clinical data recorded.…”

Section: Antipsychotics and Glucose Disturbancesmentioning

confidence: 99%

See 1 more Smart Citation

Abnormal glucose metabolism in patients treated with antipsychotics

Scheen

Hert

2007

Diabetes & Metabolism

148

View full text Add to dashboard Cite

Second-generation (atypical) antipsychotic medications are of great benefit to a wide variety of people with psychiatric disorders, especially patients with schizophrenia. However, one constellation of adverse effects is an increased risk of obesity, diabetes, and metabolic syndrome. Increasing numbers of reports concerning impaired glucose tolerance, diabetes, and ketoacidosis have raised concerns about a possible association between abnormal glucose metabolism and treatment with atypical antipsychotics, although the question is still debated because of the presence of many confounding factors. A close relationship between drug-induced weight gain and risk of diabetes has been reported, emphasizing the role of insulin resistance. However, some cases of diabetes developed independently of weight gain, rather rapidly and possibly progressing to ketoacidosis, thus arguing for a severe impairment of insulin secretion. Another debated question is whether diabetes risk is a class action or a differential action. Although not fully scientifically proven yet, available evidence suggests that clozapine and olanzapine have a higher propensity to induce diabetes and metabolic syndrome compared with other atypical antipsychotic drugs, risperidone and quetiapine. Despite more limited available data, amisulpride, aripiprazole and ziprazidone showed less likelihood of precipitating diabetes. Interestingly, reversibility of drugrelated diabetes has been reported with aripiprazole. The choice of atypical antipsychotic medication for a specific patient depends on many factors, but the likelihood of developing diabetes should become an important consideration. When prescribing an atypical antipsychotic, a commitment to careful baseline screening and follow-up monitoring is essential in order to mitigate the risk of developing diabetes and associated complications.Keywords: antipsychoticsa; schizophrenia ; diabetes ; impaired glucose tolerance ; metabolic syndrome ; review RésuméLes antipsychotiques de seconde génération, appelés aussi antipsychotiques atypiques, ont apporté une aide précieuse dans la prise en charge de nombreux patients psychiatriques, en particulier ceux avec schizophrénie. Cependant, ils semblent associés à une constellation d'effets indésirables métaboliques, avec un risque accru d'obésité, de diabète et de syndrome métabolique. Un nombre croissant de publications à propos de cas de diminution de tolérance au glucose, de diabète et d'acidocétose chez des patients traités avec des antipsychotiques atypiques plaident pour une association causale possible entre une anomalie du métabolisme du glucose et le traitement par antipsychotique atypique, même si la question reste controversée suite à la présence de nombreux facteurs confondants. Une relation étroite entre la prise de poids induite par la médication et le risque accru de diabète a été rapportée, insistant sur le rôle de l'insulinorésistance. Pourtant, certains cas de diabète se développent indépendamment de toute prise pondérale, avec une évolution...

show abstract

Section: Psychiatric Disorders and Diabetessupporting

confidence: 67%

Section: Antipsychotics and Glucose Disturbancesmentioning

confidence: 99%

Abnormal glucose metabolism in patients treated with antipsychotics

Scheen

Hert

2007

Diabetes & Metabolism

148

View full text Add to dashboard Cite

show abstract

“…In consistent with previous studies, waist circumference was larger in women (17,32). De Hert and associates (50) reported that the most common MetS criteria among first episode, (<1.5 years), new onset (1.5-10 years), subchronic (10-20 years) and chronic (>20 years) schizophrenia patients was waist circumference. These findings suggest that waist circumference is an important criteria to follow the patients.…”

Section: One Of the Most Important Causes For Mets In Patientsmentioning

confidence: 99%

The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patients

Sarısoy¹,

Böke²,

Öztürk³

et al. 2013

Dusunen Adam

View full text Add to dashboard Cite

The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patientsObjective: The purpose of this study was to determine the frequency of metabolic syndrome (MetS) in schizophrenia patients who are receiving treatment with antipsychotic drugs and also the sociodemographic and clinical characteristics of schizophrenia patients with MetS.Methods: 111 schizophrenia patients diagnosed on the basis of DSM-IV diagnostic criteria and receiving antipsychotic therapy for at least 3 months were included in the study. MetS was diagnosed on the basis of International Diabetes Fedaration (IDF) diagnostic criteria. Schizophrenia patient groups with and without diagnosed MetS were compared in terms of sociodemographic and clinical characteristics.Results: MetS was determined in 27% of the patients. The most commonly determined parameter was elevated waist circumference (65.8%). The least common parameter was elevated blood pressure (10.8%).The waist circumference parameter in women and the blood pressure parameter in men were more frequently determined. No difference was determined between schizophrenia patients with or without MetS in terms of sociodemographic characteristics, schizophrenia subtypes and symptoms or other clinical characteristics. Conclusion:MetS is a significant problem in schizophrenia patients receiving antipsychotic therapy. Elevated waist circumference is an important parameter in monitoring. The findings in the literature regarding the relationship between MetS and sociodemographic and clinical characteristics are contradictory. No correlation was determined in our study. Further studies are now needed to shed light on this subject. There would seem to be no correlation between MetS and schizophrenia subtypes and symptoms.

show abstract

“…Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1][2][3][4][5] as well as an increased risk for cancer [6,7].…”

Section: Introductionmentioning

confidence: 99%